Key facts
| Price (PPV) | 990 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | cinacalcet |
| Class | Calcium homeostasis |
| ATC code | H05BX01 |
| Manufacturer | SPIMACO |
| Presentation | Boite de 28 |
| Hospital price | 710 MAD |
| Data collected on | 9/8/2026 |
Indications
Pour le traitement de l'hyperparathyroïdie secondaire chez les patients atteints de maladie rénale chronique, bénéficiant d'une dialyse. Pour le traitement de l'hypercalcémie chez les patients atteints de cancer de la parathyroïde ou chez les patients atteints d'hyperparathyroïdie primaire pour qui la parathyroïdectomie n'est pas une option thérapeutique.
Find an open pharmacy
On-call pharmacies near you
About Decalcine 30 mg
Decalcine 30 mg belongs to the calcium homeostasis therapeutic class. In Morocco, this drug is marketed by SPIMACO and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Decalcine 30 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Decalcine 30 mg
Answers to common questions from Moroccan patients about this drug.